We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Chinese Firm Sinovac Biotech Says It Is 99% Sure that Its COVID-19 Vaccine Will Work

By HospiMedica International staff writers
Posted on 01 Jun 2020
Print article
Illustration
Illustration
Sinovac Biotech Ltd. (Beijing, China), a biopharmaceutical company, has stated that the company is 99% sure that its COVID-19 vaccine, called CoronaVac, will work.

Sinovac has received approval from government authorities to conduct both Phase I and Phase II human clinical trials of its COVID-19 vaccine in China. The company has made significant process in the development of CoronaVac. The Phase I clinical trial, which evaluated the safety, tolerance, and preliminary immunogenicity of the COVID-19 vaccine, commenced in April. The company recently published preclinical results regarding CoronaVac, noting that the vaccine candidate was safe and provided protection to rhesus macaques (monkeys) through an animal challenge study.

After preliminary observation of the safety profile of CoronaVac in the Phase I study, Sinovac began conducting Phase II trial of its coronavirus vaccine in May that involved more than 1,000 volunteers. The Phase II clinical trial will evaluate the immunogenicity and safety of CoronaVac in a larger population in order to define dosage, regimen and immunization schedule. The company is now in preliminary discussions to hold the Phase III trial of its coronavirus vaccine, with the final part of the process planned to be conducted in the UK.

Sinovac has secured USD 15 million in funding to accelerate its COVID-19 vaccine development and is constructing a commercial vaccine production plant that is expected to manufacture up to 100 million doses of CoronaVac annually. According to a report by Sky News, when Luo Baishan, a researcher at Sinovac, was asked by their reporter whether he thought the vaccine would be successful, he said, "Yes, yes. It must be successful… 99% (sure)."

Related Links:
Sinovac Biotech Ltd.

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Automated External Defibrillator
HeartStart OnSite AED
New
Digital Brain Electric Activity Mapping Device
KT88

Print article

Channels

Critical Care

view channel
Image: Tissue plasminogen activator working to dissolving brain clot and improving blood flow to the part of the brain being deprived (Photo courtesy of American Heart Association)

Injecting Clot-Dissolving Drug After Removing Large Brain Artery Clot Improves Stroke Outcomes

Approximately 1 in 5 ischemic strokes, which are caused by a clot, occur due to a blockage in a large artery in the brain (large vessel occlusions). The standard treatment for this type of stroke is the... Read more

Surgical Techniques

view channel
Image: The KeyScope low-cost laparoscope enables high resolution surgical imaging (Photo courtesy of Barnes et al., doi 10.1117/1.BIOS.2.2.022302)

Low-Cost, Robust Laparoscope Addresses Cost, Power and Sterilization Challenges

Laparoscopic surgery, a minimally invasive technique, has revolutionized surgical practices in high-income countries. This method involves using a laparoscope to perform operations through small incisions,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.